KFAS
KYMR icon

Keating Financial Advisory Services’s Kymera Therapeutics KYMR Stock Holding History

Keating Financial Advisory Services’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.21K Hold
28
– – ﹤0.01% 1749
2026
Q1 		$2.33K Buy
28
+9
+47% +$713 ﹤0.01% 1784
2025
Q4 		$1.48K Buy
+19
New +$1.28K ﹤0.01% 1682

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Keating Financial Advisory Services's KYMR Position: Q2 2026 in Review

Keating Financial Advisory Services held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 28 shares worth $3.21K. The position accounts for ﹤0.01% of the portfolio, ranked #1749.

Keating Financial Advisory Services first reported a position in KYMR in Q4 2025 and has held it in 3 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Keating Financial Advisory Services held 28 shares of Kymera Therapeutics worth $3.21K as of Q2 2026.
  • Keating Financial Advisory Services left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1749 holding.
  • Keating Financial Advisory Services first reported a position in Kymera Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.